Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00816543 | Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma | PHASE2 | COMPLETED | 41 | — | — | Dec 1, 2008 | May 1, 2012 | Dec 18, 2012 | 1 | South Korea |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy. |
| Name | Type | Description |
|---|---|---|
| DOCETAXEL | DRUG | 50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles. |
| S-1 | DRUG | 80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year. |
| OXALIPLATIN | DRUG | 100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles. |
Inclusion criteria: * Patients with histologically confirmed, newly diagnosed, localized gastric or gastro-esophageal adenocarcinoma, that is considered operable. * The bulk of disease must be localized in the stomach, although the gastroesophageal junction may be involved. * Patients with T3 ...